C. Fletcher

G. Davis, N. Terrault, T. Schiano, 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Correlation between Plasma, Intracellular, and Cervical Tissue Levels of Raltegravir at Steady-State Dosing in Healthy Women

C. Fletcher, Theodore J. Cory, C. Mitchell, 2014, Antimicrobial Agents and Chemotherapy.

A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts.

C. Fletcher, B. Robbins, Sarah R Nelson, 2012, Journal of pharmaceutical and biomedical analysis.

Diminished Peripheral CD29hi Cytotoxic CD4+ T Cells Are Associated With Deleterious Effects During SIV Infection

C. Fletcher, S. Buch, H. Fox, 2021, Frontiers in Immunology.

Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review

C. Fletcher, A. Podany, Joshua P. Havens, 2019, Clinical Pharmacokinetics.

Impact of Different Low‐Dose Ritonavir Regimens on Lipids, CD36, and Adipophilin Expression

C. Fletcher, L. Waters, M. Boffito, 2009, Clinical pharmacology and therapeutics.

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

John L. Johnson, K. Dooley, R. Chaisson, 2020, Contemporary clinical trials.

Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial.

W. Bishai, A. Diacon, S. Swindells, 2020, The Lancet. Microbe.

Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC/MS/MS.

C. Fletcher, A. Podany, B. Robbins, 2015, Journal of pharmaceutical and biomedical analysis.

Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.

C. Fletcher, A. Avihingsanon, V. Klinbuayaem, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients

C. Aquilante, C. Fletcher, P. Anderson, 2008, Journal of acquired immune deficiency syndromes.

An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children

S. Spector, C. Fletcher, K. Singh, 2005, AIDS.

Isoniazid Pharmacokinetics, Pharmacodynamics, and Dosing in South African Infants

S. Madhi, C. Fletcher, V. Carey, 2012, Therapeutic drug monitoring.

Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology.

C. Fletcher, P. Anderson, Lane R. Bushman, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.

C. Fletcher, S. Pelton, R. Yogev, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.

D. Katzenstein, R. Haubrich, S. Lagakos, 2002, The Journal of infectious diseases.

Competing drug–drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884

D. Katzenstein, R. Haubrich, M. Fischl, 2000, AIDS.

Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review

C. Fletcher, A. Podany, Michelle Pham, 2020, Clinical Pharmacokinetics.

Quantification of Cell-Associated Atazanavir, Darunavir, Lopinavir, Ritonavir, and Efavirenz Concentrations in Human Mononuclear Cell Extracts

C. Fletcher, A. Podany, B. Robbins, 2014, Antimicrobial Agents and Chemotherapy.

The critical need for alternative antiretroviral formulations, and obstacles to their development.

C. Flexner, S. Swindells, C. Fletcher, 2011, The Journal of infectious diseases.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.

J. Mellors, J. Coffin, S. Swindells, 2009, The Journal of infectious diseases.

Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy.

C. Fletcher, P. Anderson, R. Brundage, 1999, AIDS.

Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda

C. Fletcher, D. Hom, M. Fowler, 2002, AIDS.

In-vitro Immunomodulatory activity of Azadirachta indica A.Juss. Ethanol: water mixture against HIV associated chronic CD4+ T-cell activation/ exhaustion

C. Fletcher, S. Byrareddy, B. Bagaya, 2021, BMC Complementary Medicine and Therapies.

Sex Differences in Lopinavir and Ritonavir Pharmacokinetics Among HIV‐Infected Women and Men

J. Park, C. Fletcher, J. Currier, 2011, Journal of clinical pharmacology.

Successful Use of Reduced‐Dose Efavirenz in a Patient with Human Immunodeficiency Virus Infection: Case Report and Review of the Literature

M. Witt, C. Fletcher, A. Saitoh, 2008, Pharmacotherapy.

Morphine suppresses peripheral responses and transforms brain myeloid gene expression to favor neuropathogenesis in SIV infection

C. Guda, C. Fletcher, S. Buch, 2022, bioRxiv.

Human pharmacokinetics of the antiviral drug DHPG

H. Balfour, C. Fletcher, P. Miranda, 1986, Clinical pharmacology and therapeutics.

A Antiretroviral Drug Penetration into Lymphoid Tissue

C. Fletcher, A. Podany, 2015 .

Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells.

C. Fletcher, P. Anderson, Lane R. Bushman, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Adipocytes impair efficacy of antiretroviral therapy

C. Fletcher, J. Lake, A. Grattoni, 2018, Antiviral research.

Evaluation of Oral Acyclovir Therapy

B. Bean, C. Fletcher, D. C. Mcleod, 1985, Drug intelligence & clinical pharmacy.

Alterations in P-Glycoprotein Expression and Function Between Macrophage Subsets

C. Fletcher, Hui He, Santosh Kumar, 2016, Pharmaceutical Research.

Real‐Time and Wireless Assessment of Adherence to Antiretroviral Therapy With Co‐Encapsulated Ingestion Sensor in HIV‐Infected Patients: A Pilot Study

E. Daar, C. Fletcher, M. Rosen, 2019, Clinical and translational science.

Enfuvirtide, a new drug for HIV infection

C. Fletcher, 2003, The Lancet.

Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay

C. Fletcher, S. Byrareddy, A. Podany, 2018, Scientific Reports.

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women

C. Fletcher, M. V. van Kasteren, E. Capparelli, 2016, Front. Pharmacol..

Plasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1-Infected Patients

C. Fletcher, P. Havens, J. Kiser, 2011, Antimicrobial Agents and Chemotherapy.

Continuous infusion of high-dose acyclovir for serious herpesvirus infections

B. Bean, H. Balfour, C. Fletcher, 1989, Antimicrobial Agents and Chemotherapy.

Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy.

A. Berglund, J. Lifson, A. Haase, 2015, The Journal of infectious diseases.

Impact of Nucleoside Reverse Transcriptase Inhibitors on Mitochondria in Human Immunodeficiency Virus Type 1-Infected Children Receiving Highly Active Antiretroviral Therapy

S. Spector, C. Fletcher, A. Saitoh, 2007, Antimicrobial Agents and Chemotherapy.

Effects of Long‐Term Drugs on Alfentanil Clearance in Patients Undergoing Renal Transplantation

C. Fletcher, D. E. Koehntop, S. Noormohamed, 1994, Pharmacotherapy.

Pharmacologic approaches to HIV-associated neurocognitive disorders.

C. Fletcher, H. Fox, Sean N. Avedissian, 2020, Current opinion in pharmacology.

Editorial commentary: cerebrospinal fluid inhibitory quotients of antiretroviral drugs.

C. Fletcher, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Overcoming pharmacologic sanctuaries

T. Schacker, C. Fletcher, M. Stevenson, 2013, Current opinion in HIV and AIDS.

HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety

C. Fletcher, A. Podany, Sean N. Avedissian, 2020, Drugs.

Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS

H. Balfour, C. Fletcher, F. Rhame, 1997, Antimicrobial agents and chemotherapy.

Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection

S. Swindells, E. Acosta, C. Fletcher, 2012, AIDS.

Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults

E. Acosta, C. Fletcher, V. Carey, 2016, Journal of the Pediatric Infectious Diseases Society.

One Month of Rifapentine plus Isoniazid to Prevent HIV‐Related Tuberculosis

R. Chaisson, S. Swindells, C. Fletcher, 2019, The New England journal of medicine.

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial

A. Perelson, S. Pedersen, R. Ribeiro, 2022, Nature Microbiology.

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Karen L. Price, A. Perelson, R. Ribeiro, 2022, Nature Communications.

Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19

A. Perelson, M. Hughes, W. Fischer, 2021, medRxiv.

A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection

C. Fletcher, S. Blanchard, R. McKinney, 1999, Pediatrics.

Current Status and Future Prospects of Therapeutic Drug Monitoring and Applied Clinical Pharmacology in Antiretroviral Therapy

M. Kurowski, C. Flexner, E. Acosta, 2005, Antiviral therapy.

Ganciclovir pharmacokinetics during renal impairment

C. Fletcher, K. Lake, M. Pritzker, 1988, Antimicrobial Agents and Chemotherapy.

Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts.

H. Balfour, C. Fletcher, A. Erice, 1987, JAMA.

Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors

C. Fletcher, A. Podany, K. Scarsi, 2016, Clinical Pharmacokinetics.

Antiretroviral drug interactions.

E. Acosta, C. Fletcher, 1995, International journal of antimicrobial agents.

Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults

C. Fletcher, J. Gerber, P. Anderson, 2007, AIDS.

Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression

J. Ananworanich, T. Schacker, C. Fletcher, 2022, AIDS.

The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV‐Infected Persons

T. Schacker, C. Fletcher, J. Baker, 2020, Clinical pharmacology and therapeutics.

Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV‐infected Subjects

B. Gazzard, C. Fletcher, M. Boffito, 2008, Clinical pharmacology and therapeutics.

Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide

S. Swindells, C. Fletcher, A. Podany, 2018, AIDS.

The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards.

C. Fletcher, Lane R. Bushman, T. Delahunty, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Effect of blood exchange on acyclovir clearance in an infant with neonatal herpes.

H. Balfour, C. Fletcher, J. Englund, 1987, The Journal of pediatrics.

SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ANTIRETROVIRAL THERAPY.

M. Hughes, R. Gross, A. Collier, 2020, Journal of acquired immune deficiency syndromes.

Persistent HIV-1 replication maintains the tissue reservoir during therapy

Trevor Bedford, Sergei L. Kosakovsky Pond, Angela R. McLean, 2015, Nature.

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals

C. Fletcher, P. Anderson, T. Kakuda, 2003, AIDS.

Concentration‐controlled zidovudine therapy

C. Gross, H. Balfour, E. Acosta, 1998, Clinical pharmacology and therapeutics.

Antiretroviral drug-drug interaction considerations for HIV-infected children.

C. Fletcher, 2009, The Pediatric infectious disease journal.

Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team.

J. McNamara, S. Staprans, J. Church, 2000, The Journal of infectious diseases.

Semen Extracellular Vesicles From HIV-1-Infected Individuals Inhibit HIV-1 Replication In Vitro, and Extracellular Vesicles Carry Antiretroviral Drugs In Vivo.

J. L. Welch, C. Fletcher, J. Stapleton, 2020, Journal of acquired immune deficiency syndromes.

Pharmacotherapy of Disseminated Histoplasmosis in Patients with AIDS

C. Fletcher, R. Drew, S. Goodwin, 1993, The Annals of pharmacotherapy.

Effect of Infusion Rate on Amphotericin B-Associated Febrile Reactions

C. Fletcher, J. Cleary, D. Weisdorf, 1988, Drug intelligence & clinical pharmacy.

Textbook of Pediatric HIV Care: Antiretroviral drug interactions

C. Fletcher, T. Kakuda, 2005 .

Pharmacokinetics and safety of high‐dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation

H. Balfour, C. Fletcher, B. Chinnock, 1988, Clinical pharmacology and therapeutics.

Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings

K. Ruxrungtham, R. Gross, S. Kerr, 2021, AIDS.

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.

E. Acosta, C. Fletcher, P. Anderson, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of Ganciclovir for Cytomegalovirus Disease

H. Balfour, C. Fletcher, 1989, DICP : the annals of pharmacotherapy.

Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir.

H. Balfour, D. Dunn, R. Bolman, 1991, Transplantation.

A Risk-Benefit Evaluation of Aciclovir for the Treatment and Prophylaxis of Herpes Simplex Virus Infections

C. Fletcher, Stephani Leflore, Peter L. Anderson, 2000, Drug safety.

Treatment of Herpesvirus Infections in Hiv-Infected Individuals

C. Fletcher, 1992, The Annals of pharmacotherapy.

Clinical Implications of CNS Penetration of Antiretroviral Drugs

C. Fletcher, R. Brundage, H. Wynn, 2002, CNS drugs.

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.

R. Chaisson, S. Swindells, C. Fletcher, 2020, The Journal of antimicrobial chemotherapy.

Intramuscular and subcutaneous administration of antiretroviral drugs, compared with oral, enhances delivery to lymphoid tissues in BALB/c mice.

C. Fletcher, Sushil Kumar, N. Gautam, 2021, The Journal of antimicrobial chemotherapy.

Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis

C. Fletcher, M. Mohan, S. Byrareddy, 2021, World journal of gastroenterology.

The use of β-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection

J. Mellors, D. Margolis, C. Fletcher, 2007, AIDS.

Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir

Peter L. Anderson, Frank S. Rhame, Courtney V. Fletcher, 2001, Antimicrobial Agents and Chemotherapy.

Changes in sleep quality and brain wave patterns following initiation of an efavirenz‐containing triple antiretroviral regimen

B. Gazzard, C. Fletcher, G. Moyle, 2006, HIV medicine.

Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma.

C. Fletcher, D. Weller, R. Remmel, 2000, Clinical chemistry.

Zidovudine triphosphate and lamivudine triphosphate concentration–response relationships in HIV-infected persons

C. Fletcher, D. Weller, P. Anderson, 2000, AIDS.

Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS.

C. Fletcher, Lane R. Bushman, Courtney V Fletcher, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.

D. Katzenstein, R. Haubrich, S. Lagakos, 2000, The Journal of infectious diseases.

Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir-Ritonavir in Adolescents and Young Adults with Human Immunodeficiency Virus Infection

D. Harris, C. Fletcher, B. Kapogiannis, 2007, Antimicrobial Agents and Chemotherapy.

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.

M. Gersten, L. Mofenson, S. Spector, 1999, The New England journal of medicine.

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.

C. Fletcher, R. Remmel, N. Calles, 1998, The Journal of pediatrics.

Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.

C. Fletcher, A. Podany, Joshua P. Havens, 2020, The Journal of antimicrobial chemotherapy.

Zalcitabine

C. Fletcher, M. Shelton, G. Morse, 1993, The Annals of pharmacotherapy.

Current Perspectives on Antiretroviral Therapy

C. Fletcher, 1993, Pharmacotherapy.

The Effect of Cimetidine and Ranitidine Administration With Zidovudine

C. Fletcher, Henry H. Balfour, W. Keith Henry, 1995, Pharmacotherapy.

Pharmacokinetics and Safety of Concentration‐Controlled Oral Zidovudine Therapy

H. Balfour, E. Acosta, C. Fletcher, 1997, Pharmacotherapy.

Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

D. Katzenstein, R. Haubrich, E. Acosta, 2004, The Journal of infectious diseases.

Variability in Zidovudine Serum Concentrations

C. Fletcher, Henry H. Balfour, 1996, Pharmacotherapy.

Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.

J. Schapiro, C. Flexner, T. Blaschke, 2006 .

Therapeutic drug monitoring in HIV infection: current status and future directions

R. Haubrich, M. Kurowski, C. Fletcher, 2002, AIDS.

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

Richard C Brundage, Keith Henry, C. Gross, 2002, AIDS.

Acyclovir Pharmacokinetic Parameters After Multiple-Dose Oral

E. Acosta, C. Fletcher, 2017 .

Treatment of resistant herpes simplex virus with continuous-infusion acyclovir.

C. Fletcher, J. Englund, E. Hill, 1990, JAMA.

Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS

W. K. Henry, C. Crumpacker, H. Balfour, 1996, Antimicrobial agents and chemotherapy.

Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex.

H. Balfour, C. Fletcher, K. Henry, 1988, JAMA.

Pharmacologic Considerations for Therapeutic Success with Antiretroviral Agents

C. Fletcher, 1999, The Annals of pharmacotherapy.

Indinavir Concentrations and Antiviral Effect

E. Acosta, C. Fletcher, K. Henry, 1999, Pharmacotherapy.

Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children.

C. Fletcher, D. Hoody, 2003, Seminars in pediatric infectious diseases.

Acceptable Plasma Concentrations of Raltegravir and Etravirine When Administered by Gastrostomy Tube in a Patient with Advanced Multidrug‐Resistant Human Immunodeficiency Virus Infection

S. Swindells, E. Acosta, C. Fletcher, 2012, Pharmacotherapy.

Pharmacologic Characteristics of Indinavir, Didanosine, and Stavudine in Human Immunodeficiency Virus-Infected Children Receiving Combination Therapy

C. Fletcher, D. Weller, R. Remmel, 2000, Antimicrobial Agents and Chemotherapy.

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

C. Fletcher, W. Shearer, M. Kline, 1996, Pediatrics.

Pharmacometric Characterization of Efavirenz Developmental Pharmacokinetics and Pharmacogenetics in HIV-Infected Children

C. Fletcher, A. Salem, R. Brundage, 2013, Antimicrobial Agents and Chemotherapy.

Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay

C. Fletcher, S. Byrareddy, A. Podany, 2018, Scientific Reports.

Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy.

Akihiko Saitoh, S. Spector, C. Fletcher, 2006, The Journal of allergy and clinical immunology.

Longitudinal analysis of lymphocyte ratios and HIV-1 intracellular DNA levels in children.

S. Spector, C. Fletcher, S. Douglas, 2004, The Journal of infectious diseases.

Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.

S. Spector, C. Fletcher, A. Saitoh, 2002, The Journal of infectious diseases.

Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.

J. Halter, K. Schmader, D. Kuritzkes, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Workshop on HIV Infection and Aging: What Is Known and Future Research Directions

J. Halter, K. Schmader, D. Kuritzkes, 2008 .

CONCISE COMMUNICATION Patterns of Plasma Human Immunodeﬁciency Virus Type 1 RNA Response to Highly Active Antiretroviral Therapy in Infected Children

L. Mofenson, S. Spector, C. Fletcher, 2022 .

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

Steven C Johnson, Steven C. Johnson, Daniel R Kuritzkes, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.

U. Lalloo, C. Fletcher, C. Benson, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin vs. Lopinavir/Ritonavir + Daily Rifabutin for Treatment of HIV-TB Coinfection.

U. Lalloo, C. Fletcher, C. Benson, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.

C. Fletcher, C. Craig, N. Calles, 2001, The Pediatric infectious disease journal.

Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.

C. Fletcher, A. Owen, S. Cohn, 2023, Contraception.

Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.

C. Fletcher, P. Byakika-Kibwika, M. Siccardi, 2022, The Journal of antimicrobial chemotherapy.

Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.

S. Khoo, C. Fletcher, D. Back, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

J. Mellors, S. Swindells, A. DiRienzo, 2006, JAMA.

Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model

Zhe Yuan, C. Destache, Qingsheng Li, 2016, Antimicrobial Agents and Chemotherapy.

Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics

C. Fletcher, A. Podany, K. Scarsi, 2020, Scientific Reports.

Intrapatient Variability of Efavirenz Concentrations as a Predictor of Virologic Response to Antiretroviral Therapy

S. Spector, C. Fletcher, R. Brundage, 2004, Antimicrobial Agents and Chemotherapy.

Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).

C. Aquilante, D. Haas, C. Fletcher, 2016, The Journal of antimicrobial chemotherapy.

Strategies for control of zidovudine concentrations in serum

W. K. Henry, H. Balfour, C. Fletcher, 1995, Antimicrobial agents and chemotherapy.

Advances in pharmacotherapy: treatment of HIV infection

E. Acosta, C. Fletcher, 1993 .

Drug Interactions Should Be Evaluated in Patients

C. Fletcher, 2010, Clinical pharmacology and therapeutics.

Four Measures of Antiretroviral Medication Adherence and Virologic Response in AIDS Clinical Trials Group Study 359

R. Haubrich, M. Chesney, E. Acosta, 2005, Journal of acquired immune deficiency syndromes.

Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.

D. Katzenstein, R. Haubrich, R. Swanstrom, 2004, The Journal of infectious diseases.

Pharmacokinetic Characteristics of Ritonavir, Zidovudine, Lamivudine, and Stavudine in Children with Human Immunodeficiency Virus Infection

C. Fletcher, S. Pelton, R. Yogev, 2004, Pharmacotherapy.

Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site.

J. Routy, C. Fletcher, R. Bendayan, 2016, The Journal of antimicrobial chemotherapy.

Impact of Integrase Inhibition compared to non-nucleoside inhibition on HIV reservoirs in Lymphoid Tissues.

A. Haase, D. Douek, C. Reilly, 2019, Journal of acquired immune deficiency syndromes.

Impact of Integrase Inhibition Compared With Nonnucleoside Inhibition on HIV Reservoirs in Lymphoid Tissues

A. Haase, D. Douek, C. Reilly, 2019, Journal of acquired immune deficiency syndromes.

Clinical Evaluation of a Dried Blood Spot Assay for Atazanavir

T. V. Van Schooneveld, S. Swindells, C. Fletcher, 2010, Antimicrobial Agents and Chemotherapy.

Therapeutic Drug Monitoring and Drug–Drug Interactions Involving Antiretroviral Drugs

David Back, David Burger, Charles Flexner, 2005, Antiviral therapy.

Updated clinical pharmacologic considerations for HIV-1 protease inhibitors

C. Fletcher, P. Anderson, 2004, Current HIV/AIDS reports.

A rapid spin through oil results in higher cell-associated concentrations of antiretrovirals compared with conventional cell washing.

C. Fletcher, B. Robbins, Lee C Winchester, 2015, Bioanalysis.

Indinavir plasma protein binding in HIV-1-infected adults

C. Fletcher, P. Anderson, R. Remmel, 2000, AIDS.

Cryopreservation of microglia enables single-cell RNA sequencing with minimal effects on disease-related gene expression patterns

C. Fletcher, H. Fox, Meng Niu, 2021, iScience.

Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.

L. Mofenson, S. Spector, C. Fletcher, 2000, The Journal of infectious diseases.

Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options

Rahul Singh, C. Fletcher, D. Salunke, 2021, Biomedicine & Pharmacotherapy.

Impact of censoring data below an arbitrary quantification limit on structural model misspecification

Courtney V. Fletcher, Wonkyung Byon, Richard C. Brundage, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

Gender differences in human pharmacokinetics and pharmacodynamics.

E. Acosta, C. Fletcher, C V Fletcher, 1994, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults: A Pilot Study

C. Aquilante, E. Schuetz, C. Fletcher, 2006, Journal of acquired immune deficiency syndromes.

Report of the AACP Educating Clinical Scientists Task Force

C. Fletcher, R. Blouin, T. Tracy, 2008 .

Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients

C. Gross, H. Balfour, D. Dunn, 1991, Antimicrobial Agents and Chemotherapy.

Implications of HIV PrEP trials results.

V. DeGruttola, C. Fletcher, D. Burns, 2011, AIDS research and human retroviruses.

Lorenzo-Redondo et al. reply

Trevor Bedford, Sergei L. Kosakovsky Pond, Angela R. McLean, 2017, Nature.

Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19)

C. Fletcher, S. Reid, S. Byrareddy, 2020, Journal of Molecular Medicine.

Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption

A. Haase, D. Douek, A. Khoruts, 2015, Proceedings of the National Academy of Sciences.

CD8+ cells and small viral reservoirs facilitate post-ART control of SIV in Mauritian cynomolgus macaques

D. O’Connor, T. Friedrich, B. Keele, 2023, bioRxiv.

Agents for treating human immunodeficiency virus infection.

E. Acosta, C. Fletcher, 1994, American journal of hospital pharmacy.

The Contributions of Clinical Pharmacology to HIV Cure Research

C. Fletcher, S. Byrareddy, A. Acharya, 2021, Clinical pharmacology and therapeutics.

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection

C. Fletcher, N. Calles, R. Brundage, 2002, Clinical pharmacology and therapy.

Efavirenz Pharmacokinetics in HIV-1-Infected Children Are Associated With CYP2B6-G516T Polymorphism

S. Spector, C. Fletcher, A. Saitoh, 2007, Journal of acquired immune deficiency syndromes.

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.

K. Tashima, D. Kuritzkes, D. Clifford, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Pharmacogenetics of NAT2 Enzyme Maturation in Perinatally HIV Exposed Infants Receiving Isoniazid

C. Fletcher, C. Werely, D. D’Argenio, 2012, Journal of clinical pharmacology.

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

Alan S Perelson, Stephen W Wietgrefe, Ann Thorkelson, 2014, Proceedings of the National Academy of Sciences.

Defining total-body AIDS-virus burden with implications for curative strategies

J. Lifson, A. Haase, D. Douek, 2017, Nature Medicine.

Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice.

C. Fletcher, N. Gautam, Y. Alnouti, 2019, The Journal of antimicrobial chemotherapy.

Transplantation of CCR5∆32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection

D. Richman, J. Wagner, A. Haase, 2018, Open forum infectious diseases.

Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial

J. Karn, J. Safrit, D. Douek, 2022, Nature Medicine.

Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model

Zhe Yuan, C. Destache, Qingsheng Li, 2016 .

Pharmacist interventions to improve prescribing of vancomycin and tobramycin.

C. Fletcher, R. M. Giese, J. Rodman, 1986, American journal of hospital pharmacy.

Semen and Serum Pharmacokinetics of Zidovudine and Zidovudine‐Glucuronide in Men with HIV‐1 Infection

H. Balfour, C. Fletcher, P. Anderson, 2000, Pharmacotherapy.

Clinical pharmacologic considerations for HIV-1 protease inhibitors

C. Fletcher, P. Anderson, 2001, Current infectious disease reports.

Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury

Lisa H. Merck, J. Koopmeiners, T. Schacker, 2022, JAMA network open.

Effect of losartan on hospitalized patients with COVID-19-induced lung injury: A randomized clinical trial

Lisa H. Merck, J. Koopmeiners, T. Schacker, 2021, medRxiv.

Potential confusion with antiretroviral drugs.

E. Acosta, C. Fletcher, T. Kakuda, 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Efavirenz liquid formulation in human immunodeficiency virus-infected children

S. Spector, C. Fletcher, S. Douglas, 2002, The Pediatric infectious disease journal.

The Clinical Pharmacology of Nucleoside Reverse Transcriptase Inhibitors

C. Fletcher, J. Kiser, 2007 .

A novel 4-cell in-vitro blood-brain barrier model and its characterization by confocal microscopy and TEER measurement

C. Fletcher, A. Podany, Sean N. Avedissian, 2023, Journal of Neuroscience Methods.

Antiretroviral Drug Transporters and Metabolic Enzymes in Circulating Monocytes and Monocyte-Derived Macrophages of ART-Treated People Living With HIV and HIV-Uninfected Individuals

J. Routy, C. Fletcher, R. Bendayan, 2021, Journal of acquired immune deficiency syndromes.

Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy

R. Ribeiro, E. Daar, D. Smith, 2021, medRxiv.

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection

M. Hughes, C. Fletcher, J. Currier, 2022, Clinical pharmacology and therapeutics.

Accelerator Mass Spectrometry Measurement of Intracellular Concentrations of Active Drug Metabolites in Human Target Cells In Vivo

C. Flexner, C. Fletcher, W. Hubbard, 2010, Clinical pharmacology and therapeutics.

Prevention of cytomegalovirus disease with oral acyclovir

H. Balfour, D. Dunn, C. Fletcher, 1991 .

Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy

E. Acosta, C. Fletcher, J. Gerber, 2005, AIDS (London).

Pharmacokinetics of Co-encapsulated Antiretrovirals with Ingestible Sensors.

E. Daar, C. Fletcher, M. Rosen, 2020, AIDS research and human retroviruses.

Comparative Pharmacokinetics of Zidovudine in Healthy Volunteers and in Patients With AIDS With and Without Hepatic Disease

H. Balfour, C. Fletcher, C. Beatty, 1992, Pharmacotherapy.

Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma.

B. Larder, D. Haas, C. Fletcher, 2000, AIDS research and human retroviruses.

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.

A. Trkola, T. Ketas, I. Lowy, 2000, The Journal of infectious diseases.

Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine

R. Chaisson, D. Haas, S. Swindells, 2020, Pharmacogenetics and genomics.

Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L‐Dopa‐induced dyskinesia in parkinsonian rats

C. Fletcher, S. Papa, R. Amara, 2020, Genes, brain, and behavior.

Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children.

J. Church, C. Fletcher, J. Moye, 2007, The Journal of allergy and clinical immunology.

Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial

E. Daar, G. Savage, C. Fletcher, 2022, EBioMedicine.

Patterns of Antibiotic Use and Expenditures During 7 Years at a University Hospital

C. Fletcher, J. Rodman, D. Metzler, 1990, Pharmacotherapy.

Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19

E. Daar, C. Fletcher, C. Moser, 2023, JAMA network open.

Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents

L. Mofenson, G. Aldrovandi, C. Fletcher, 2011, AIDS.

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

E. Daar, C. Fletcher, C. Moser, 2023, Annals of Internal Medicine.

Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients

S. Swindells, K. Robertson, C. Fletcher, 2017, The Journal of antimicrobial chemotherapy.

The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV‐infected Patients

C. Aquilante, C. Fletcher, Lane R. Bushman, 2008, Clinical pharmacology and therapeutics.

Impact of Integrase Inhibition Compared With Nonnucleoside Inhibition on HIV Reservoirs in Lymphoid Tissues

A. Haase, D. Douek, C. Reilly, 2019, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in HIV‐infected Children Participating in an Area‐under‐the‐curve Controlled Trial

L. Mofenson, S. Spector, C. Fletcher, 2008, Clinical pharmacology and therapeutics.

Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug Regimen

M. Keller, C. Fletcher, A. Podany, 2016, Journal of the Pediatric Infectious Diseases Society.

CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid

C. Fletcher, P. Anderson, R. Brundage, 2002, Clinical pharmacology and therapeutics.

A rapid spin through oil results in higher cell-associated concentrations of antiretrovirals compared with conventional cell washing.

C. Fletcher, B. Robbins, Lee C Winchester, 2015, Bioanalysis.

CD8+ cells and small viral reservoirs facilitate post-ART control of SIV replication in M3+ Mauritian cynomolgus macaques initiated on ART two weeks post-infection

T. Friedrich, B. Keele, C. Fletcher, 2023, PLoS pathogens.

One Month of Rifapentine plus Isoniazid to Prevent HIV‐Related Tuberculosis

R. Chaisson, S. Swindells, C. Fletcher, 2019, The New England journal of medicine.

ACE-2, TMPRSS2, and Neuropilin-1 Receptor Expression on Human Brain Astrocytes and Pericytes and SARS-CoV-2 Infection Kinetics

C. Fletcher, S. Byrareddy, A. Podany, 2023, International journal of molecular sciences.

Translating Efficacy into Effectiveness in Antiretroviral Therapy

C. Fletcher, 2012, Drugs.

Antiretroviral therapy for HIV-infected infants: progress and pitfalls.

C. Fletcher, 2004, AIDS.

Erratum: Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda (Aids (2002) 16 (1391-1400))

C. Fletcher, D. Hom, M. Fowler, 2002 .